

Diagnosis and Treatment of Peptic Ulcer Disease and *H. pylori* Infection

JULIA FASHNER, MD, and ALFRED C. GITU, MD, *Florida State University College of Medicine Family Medicine Residency, Lee Memorial Health System, Fort Myers, Florida*

The most common causes of peptic ulcer disease (PUD) are *Helicobacter pylori* infection and use of nonsteroidal anti-inflammatory drugs (NSAIDs). The test-and-treat strategy for detecting *H. pylori* is appropriate in situations where the risk of gastric cancer is low based on age younger than 55 years and the absence of alarm symptoms. Most other patients should undergo upper endoscopy to rule out malignancy and other serious causes of dyspepsia. Urea breath tests and stool antigen tests are most accurate for identifying *H. pylori* infection and can be used to confirm cure; serologic tests are a convenient but less accurate alternative and cannot be used to confirm cure. Treatment choices include standard triple therapy, sequential therapy, quadruple therapy, and levofloxacin-based triple therapy. Standard triple therapy is only recommended when resistance to clarithromycin is low. Chronic use of NSAIDs in patients with *H. pylori* infection increases the risk of PUD. Recommended therapies for preventing PUD in these patients include misoprostol and proton pump inhibitors. Complications of PUD include bleeding, perforation, gastric outlet obstruction, and gastric cancer. Older persons are at higher risk of PUD because of high-risk medication use, including antiplatelet drugs, warfarin, selective serotonin reuptake inhibitors, and bisphosphonates. (*Am Fam Physician*. 2015;91(4):236-242. Copyright © 2015 American Academy of Family Physicians.)

CME This clinical content conforms to AAFP criteria for continuing medical education (CME). See CME Quiz Questions on page 230.

Author disclosure: No relevant financial affiliations.

► **Patient information:** A handout on this topic, written by the authors of this article, is available at <http://www.aafp.org/afp/2015/0215/p236-s1.html>.

Dyspepsia is characterized by epigastric pain, discomfort, or a burning sensation.¹ An important cause of dyspepsia is peptic ulcer disease (PUD), which includes gastric and duodenal ulcers. Although PUD is most commonly caused by *Helicobacter pylori* infection or use of nonsteroidal anti-inflammatory drugs (NSAIDs), other diagnoses should be considered (*Table 1*).

Pathophysiology of *H. pylori*

H. pylori, a gram-negative, helical, rod-shaped bacterium, colonizes the gastric mucosa of approximately one-half of the world population² and an estimated 30% to 40% of the U.S. population.³ *H. pylori* is present in 95% of patients with duodenal ulcers and in 70% of those with gastric ulcers.⁴ It is typically transmitted via the fecal-oral route during early childhood and persists for decades. The bacterium is a known cause of gastric and duodenal ulcers⁵ and is a risk factor for mucosa-associated lymphoid tissue (MALT) lymphoma and gastric adenocarcinoma.^{6,7}

Diagnosis

The history and physical examination are important to identify patients at risk of ulcer, perforation, bleeding, or malignancy. However, a systematic review of models using risk factors, history, and symptoms found that they did not reliably distinguish between functional dyspepsia and organic disease.⁸ Therefore, the test-and-treat strategy for *H. pylori* is recommended for patients with dyspepsia who have no alarm symptoms.¹

The American College of Gastroenterology (ACG) recommends testing for *H. pylori* infection in patients with active PUD or history of PUD, dyspepsia symptoms, or gastric MALT lymphoma.³ The rationale for testing patients with a history of PUD who are currently asymptomatic is that detecting and treating *H. pylori* infection can reduce the risk of recurrence. The test-and-treat strategy for detecting *H. pylori* is appropriate in patients with dyspepsia and low risk of gastric cancer (age younger than 55 years and no alarm symptoms such as unexplained weight loss, progressive dysphagia, odynophagia,

SORT: KEY RECOMMENDATIONS FOR PRACTICE

Clinical recommendation	Evidence rating	References
Use the test-and-treat strategy for patients with dyspepsia who are younger than 55 years and have no alarm symptoms for gastric cancer. Use endoscopy for all other patients.	A	1-4
Confirm eradication of <i>Helicobacter pylori</i> after therapy in patients with <i>H. pylori</i> -associated ulcer, continued dyspeptic symptoms, mucosa-associated lymphoid tissue lymphoma, and resection of gastric cancer.	C	2
Non-bismuth-based quadruple therapy (10 days of a proton pump inhibitor, amoxicillin 1 g, clarithromycin 500 mg [Biaxin], and metronidazole 500 mg [Flagyl] or tinidazole 500 mg [Tindamax] twice daily) has the highest success rate in eradicating <i>H. pylori</i> , although other regimens may also be used.	A	12, 13
For patients at low risk of gastrointestinal complications, nonsteroidal anti-inflammatory drugs may be used, whereas cotherapy with a proton pump inhibitor or misoprostol (Cytotec) is recommended for patients with moderate risk of ulcer, and they should be avoided in those with a high risk of ulcer.	C	22, 24

A = consistent, good-quality patient-oriented evidence; B = inconsistent or limited-quality patient-oriented evidence; C = consensus, disease-oriented evidence, usual practice, expert opinion, or case series. For information about the SORT evidence rating system, go to <http://www.aafp.org/afpsort>.

Table 1. Differential Diagnosis of Peptic Ulcer Disease

Commonly mistaken for peptic ulcer disease	Less commonly mistaken	Rarely mistaken
Esophagitis	Celiac disease	Abdominal aortic aneurysm
Functional dyspepsia	Cholangitis	Acute coronary syndrome
Gastritis	Cholecystitis	Barrett esophagus
Gastroenteritis	Cholelithiasis	Gastric cancer
Gastroesophageal reflux disease	Esophageal perforation	Viral hepatitis
	Inflammatory bowel disease	Zollinger-Ellison syndrome
	Irritable bowel syndrome	

recurrent vomiting, family history of gastrointestinal cancer, overt gastrointestinal bleeding, abdominal mass, iron deficiency anemia, or jaundice).¹⁻⁴ Endoscopy is recommended for patients who are 55 years or older, or who have alarm symptoms. The accuracy of diagnostic tests for *H. pylori* infection is summarized in *Table 2*.^{9,10}

UREA BREATH TESTS

Urea breath tests require the ingestion of urea labeled with the nonradioactive isotope carbon 13 or carbon 14. Specificity and sensitivity approach 100%. Urea breath testing is one option for test of cure and should be performed four to six weeks after completion of eradication therapy. Proton pump inhibitors (PPIs) must be stopped for at least two weeks before the test, and accuracy is lower in patients who have had distal gastrectomy. Cost and inconvenience are disadvantages of this test.⁸

STOOL MONOCLONAL ANTIGEN TESTS

Stool antigen tests using monoclonal antibodies are as accurate as urea breath tests if a validated laboratory-based monoclonal test is used.^{1,11} They are cheaper and require less equipment than urea breath tests. Like urea

breath tests, stool antigen tests detect only active infection and can be used as a test of cure. PPIs should be stopped for two weeks before testing, but stool antigen tests are not as affected by PPI use as are urea breath tests.

SEROLOGIC TESTS

Serologic antibody testing detects immunoglobulin G specific to *H. pylori* in serum and cannot distinguish between an active infection and a past infection. Serologic tests may be most useful in mass population surveys and in patients who cannot stop taking PPIs (e.g., those with gastrointestinal bleeding or continuous NSAID use) because the tests are not affected by PPI or antibiotic use.^{1,2}

ENDOSCOPY WITH BIOPSY

Endoscopy with biopsy is recommended to rule out cancer and other serious causes in patients 55 years or older, or with one or more alarm symptoms. In patients who have not been taking a PPI within one to two weeks of endoscopy, or bismuth or an antibiotic within four weeks, the rapid urease test performed on the biopsy specimen provides an accurate, inexpensive means of

PUD and *H. Pylori* Infection

diagnosing *H. pylori* infection.² Patients who have been on these medications will require histology, with or without rapid urease testing. Culture and polymerase chain reaction allow for susceptibility testing but are not readily available for clinical use in the United States.

Treatment

Eradication of *H. pylori* is recommended in all patients with PUD.¹ First-line therapy should have an eradication rate of more than 80%.⁴ Because pretreatment susceptibility is rarely known to the primary care physician, therapy must be chosen empirically based on regional bacterial resistance patterns, local recommendations, and drug availability. *Table 3* includes treatment options; standard triple therapy is a reasonable initial therapy where clarithromycin resistance is low.^{2-4,12-16}

Eradication heals most duodenal ulcers and greatly diminishes the risk of recurrent bleeding.³ A systematic review found that treatment of *H. pylori* infection is more effective than antisecretory noneradicating therapy (with or without long-term maintenance

antisecretory therapy) in preventing recurrent bleeding from peptic ulcer.¹⁷ Current data suggest that increasing the duration of therapy to 14 days significantly increases the eradication rate.¹⁸

TEST OF CURE

Test of cure for all patients after therapy is neither cost-effective nor practical. Indications for eradication testing with the urea breath test or stool antigen test include *H. pylori*-associated ulcer, continued dyspeptic symptoms, *H. pylori*-associated MALT lymphoma, and resection for gastric cancer.² When indicated, eradication testing should be performed at least four weeks after completion of therapy.²

STANDARD TRIPLE THERAPY

A seven- to 10-day triple drug regimen consisting of a PPI, amoxicillin 1 g, and clarithromycin 500 mg (Biaxin) twice daily has long been the first-line therapy to eradicate *H. pylori*. However, increasing resistance to clarithromycin is associated with declining eradication rates,

Table 2. Accuracy of Diagnostic Tests for *Helicobacter pylori* Infection

Tests	Sensitivity (%)	Specificity (%)	PV+ (%)	PV- (%)	Advantages	Disadvantages
Noninvasive						
Urea breath test (carbon 13)	97	100	99	1.5	Used for initial diagnosis and test of cure	Expensive and inconvenient Patient must fast for six hours
Stool monoclonal antigen tests						
Enzyme immunoassay	92	94	89	3.9	—	More expensive than immunochromatography
Immunochromatography	69 to 87	87 to 93	72 to 85	6.6 to 15	May be used in the office for rapid diagnosis	Varying reliability
Antibody tests	76 to 84	79 to 80	64 to 67	9 to 13	Lower cost Easily available	PV+ dependent on prevalence, not useful as test of cure
Invasive						
Rapid urease test	95	100	98.9	2.4	Rapid Inexpensive	Sensitivity is low in treated patients
Histology	94	99	97	3	—	Expensive
Culture	NR	100	NR	NR	Allows for susceptibility testing	Not widely available; expensive
Polymerase chain reaction	NR	NR	NR	NR	Allows for susceptibility testing	Not standardized; not widely available

NOTE: Predictive values assume a prevalence of 33%, which is typical of the U.S. population.

NR = not reported; PV+ = positive predictive value; PV- = negative predictive value.

Information from references 9 and 10.

Table 3. Treatment Regimens for *Helicobacter pylori* Infection

Type	Regimen	Duration	Eradication rate	Comments
First line				
Standard triple therapy	PPI, amoxicillin 1 g, and clarithromycin 500 mg (Biaxin) twice daily	7 to 10 days (up to 14 days)	70% to 85%	Preferred
	PPI, clarithromycin 500 mg, and metronidazole 500 mg (Flagyl) twice daily	10 to 14 days	70% to 85%	
Sequential therapy	PPI and amoxicillin 1 g twice daily, followed by PPI, clarithromycin 500 mg, and tinidazole 500 mg (Tindamax) or metronidazole 500 mg twice daily	10 days (5 days for each regimen)	> 84%	Needs validation in the United States
Second line				
Non-bismuth-based quadruple therapy (concomitant therapy)	PPI, amoxicillin 1 g, clarithromycin 500 mg, and tinidazole 500 mg or metronidazole 500 mg twice daily	10 days	90%	Less complex than sequential therapy with similar eradication rates
Bismuth-based quadruple therapy	Bismuth subsalicylate 525 mg or subcitrate 300 mg, metronidazole 250 mg, and tetracycline 500 mg, four times daily; and PPI twice daily	10 to 14 days	75% to 90%	May also be used if first-line therapy fails
Levofloxacin-based triple therapy	PPI and amoxicillin 1 g twice daily, and levofloxacin 500 mg (Levaquin) once daily	10 days		Needs validation in United States; should be used as salvage therapy only

PPI = proton pump inhibitor.

Information from references 2 through 4, and 12 through 16.

now well below 80%.¹⁹ Therefore, this regimen is not recommended where the prevalence of clarithromycin-resistant strains of *H. pylori* exceeds 15% to 20%.¹ An alternative triple drug regimen substitutes metronidazole 500 mg twice daily for amoxicillin. Adding probiotics to triple therapy, specifically *Saccharomyces boulardii* and *Lactobacillus*, has been shown to increase eradication rates (absolute increase of 9% and 5%, respectively) and decrease adverse effects of treatment, particularly diarrhea (absolute decrease of 14% and 7%, respectively).^{20,21}

SEQUENTIAL THERAPY

Sequential therapy consists of a five-day course of a PPI and amoxicillin 1 g taken twice daily, followed by a five-day course of a PPI, clarithromycin 500 mg, and metronidazole 500 mg (Flagyl) or tinidazole 500 mg (Tindamax) taken twice daily. The overall eradication rate is 84%, with an eradication rate of 73% for clarithromycin-resistant strains. A recent meta-analysis of available global data revealed that sequential therapy is superior to seven-day triple therapy, but it is not superior to 14-day triple therapy, bismuth-based quadruple therapy, or non-bismuth-based quadruple therapy.¹²

Compliance and tolerance rates of sequential therapy are similar to those of triple therapy but cost is lower, especially when the cost of failure of first-line therapy is considered. However, most studies were performed in Italy, and the ACG guideline states that sequential therapy requires validation in the United States.³

NON-BISMUTH-BASED QUADRUPLE THERAPY (CONCOMITANT THERAPY)

This approach involves the addition of metronidazole 500 mg or tinidazole 500 mg twice daily to the standard triple regimen. It is less complex than sequential therapy with similar eradication rates.^{13,14} Additionally, non-bismuth-based quadruple therapy may be more effective than sequential therapy in patients with dual antibiotic resistance to clarithromycin and metronidazole.¹⁵ It has the highest eradication rate, about 90%, even in areas with high clarithromycin and metronidazole resistance,^{22,23} but would presumably cost more than sequential therapy because clarithromycin is taken for 10 days.

BISMUTH-BASED QUADRUPLE THERAPY

This is the traditional quadruple regimen and includes a bismuth salt (subsalicylate 525 mg or subcitrate potassium 420 mg), metronidazole 250 mg, and tetracycline 375 to 500 mg, all taken four times daily, in addition to a PPI taken twice per day.² Bismuth-based quadruple therapy is often employed as salvage therapy if first-line treatment fails, but it may be used as first-line therapy in areas of high resistance or when cost is an important consideration. A three-in-one combination capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline has been developed to help reduce the pill burden, but patients still have to take three capsules four times per day in addition to a PPI. The regimen is usually given for 10 to 14 days.

PUD and *H. Pylori* Infection

LEVOFLOXACIN-BASED TRIPLE THERAPY

This is a 10-day regimen of a PPI and amoxicillin 1 g twice daily, and levofloxacin 500 mg (Levaquin) once daily. The ACG states that this regimen requires validation in the United States.³ It should be reserved for second-line therapy and is better tolerated than bismuth-based quadruple therapy.¹⁶

NSAIDs and PUD PREVENTION

Risk factors for gastrointestinal toxicity from NSAID use include older age; chronic use of high-dose NSAIDs; use of aspirin, anticoagulants, or corticosteroids; and a history of ulcer.²² Therapies aimed at protecting the mucosa include the prostaglandin analogue misoprostol (Cytotec), histamine H₂ receptor antagonists, a cyclooxygenase-2 (COX-2) inhibitor instead of a standard NSAID, and PPIs. A Cochrane review on the effectiveness of these therapies compared with placebo suggests that high-risk patients should take a COX-2 inhibitor with a PPI for the greatest gastrointestinal safety.²³

Concerns have been raised about increased cardiovascular risk with the use of COX-2 inhibitors. The ACG²² and the Canadian Association of Gastroenterology²⁴ have each developed evidence-based guidelines for the prevention of NSAID-related ulcers in patients at risk of cardiovascular disease, including those with previous cardiovascular events. The recommendations are summarized in *Table 4*.^{22,24} NSAIDs are appropriate for patients with low risk of gastrointestinal complications, whereas cotherapy with a PPI or misoprostol is preferred for patients with gastrointestinal risk factors.^{22,24} Patients at low cardiovascular risk may take traditional NSAIDs or a COX-2 inhibitor; however, the Canadian Association of Gastroenterology suggests that the use of naproxen may be appropriate for patients at high cardiovascular risk.^{22,24}

NSAIDS AND *H. PYLORI*

Peptic ulcers are more common in patients taking NSAIDs who are *H. pylori* positive compared with those who are negative (pooled odds ratio [OR] = 1.81; 95% confidence interval [CI], 1.40 to 2.36). Bleeding is also more likely to occur in patients taking NSAIDs who are *H. pylori* positive (pooled OR = 5.21; 95% CI, 3.48 to 7.78).⁵ Eradicating *H. pylori* in NSAID users reduces the likelihood of peptic ulcer by about one-half (OR = 0.43; 95% CI, 0.2 to 0.9).²⁵ However, a meta-analysis found that the use of a maintenance PPI was more effective than *H. pylori* eradication therapy for preventing NSAID-related ulcers (OR = 7.4; 95% CI, 1.3 to 44).²⁵ The ACG

guideline recommends that patients who will be on long-term NSAID therapy be tested for *H. pylori* infection, and eradication therapy should be given if positive.²²

Special Circumstances in PUD

OLDER PERSONS

Older persons are at a higher risk of PUD, in part because of high-risk medication use, including antiplatelet drugs, warfarin (Coumadin), selective serotonin reuptake inhibitors, and bisphosphonates.²⁶ Compared with younger patients, older patients have less abdominal pain when they have an ulcer.²⁷ Physicians should identify other risk factors for ulcers when older patients are taking NSAIDs, including previous ulcer, use of antiplatelet or anticoagulant medications, smoking, severe comorbidity or frailty, and alcohol abuse.²⁶ Treatment options include discontinuing or reducing the dose of NSAIDs, choosing a less damaging NSAID or changing to a COX-2 inhibitor, or starting a PPI or misoprostol. After eradication of *H. pylori*, older patients taking an NSAID may still need a maintenance PPI.²⁶ However, long-term PPI use is associated with an increased risk of *Clostridium difficile*-associated diarrhea, community-acquired pneumonia, interstitial nephritis, osteoporosis, and some vitamin and mineral malabsorptions.²⁸

CHILDREN

Although gastrointestinal symptoms are common in children, PUD is rare (24.8 per 100,000 children annually).²⁹ Recurrent abdominal pain is not associated with *H. pylori* infection, and there is conflicting evidence regarding the association between epigastric pain and *H. pylori* infection.³⁰ One study found that nausea, vomiting, and diarrhea were associated with *H. pylori*, but that abdominal pain and heartburn were not.³¹ An evidence-based clinical guideline developed by an international panel makes recommendations for *H. pylori* infection in children and adolescents. The best supported recommendations are presented in *Table 5*.³²

Complications

The complications of PUD from any etiology include bleeding, perforation, and gastric outlet obstruction.³³ Hemorrhage is the most common complication, with up to 15% of patients experiencing some degree of bleeding. In one study, the incidence of peptic ulcer hospitalizations was 5.65 per 1,000 person-years in patients taking NSAIDs without gastrointestinal protective therapy.³³ Endoscopy is considered the standard of care for patients with gastrointestinal bleed and may allow for treatment of the ulcer at the same time.²⁹

Table 4. Recommendations for Prevention of NSAID-Related Ulcer Complications

Cardiovascular risk	Gastrointestinal risk*	Recommendation	
		American College of Gastroenterology ²²	Canadian Association of Gastroenterology ²⁴
Low	Low	NSAID	NSAID
	Moderate	NSAID plus PPI or misoprostol (Cytotec)	—
	High	Alternative therapy if possible, or COX-2 inhibitor plus PPI or misoprostol	COX-2 inhibitor plus PPI
High	Low	Naproxen plus PPI or misoprostol	Naproxen
	Moderate	Naproxen plus PPI or misoprostol	—
	High	Avoid NSAID and COX-2 inhibitor; alternative therapy	Gastrointestinal concern is greater than cardiovascular concern: COX-2 inhibitor plus PPI Cardiovascular concern is greater than gastrointestinal concern: naproxen plus PPI

COX-2 = cyclooxygenase-2; NSAID = nonsteroidal anti-inflammatory drug; PPI = proton pump inhibitor.

*—Risk factors for peptic ulcers from NSAID use include older age; use of high-dose NSAID; use of aspirin, anticoagulants, or corticosteroids; and history of ulcer. Low risk = no risk factors; moderate risk = 1 or 2 risk factors; high risk = > 2 risk factors or history of previous complicated ulcer.

Information from references 22 and 24.

The incidence of perforation from PUD in the general population (not taking NSAIDs) is about one per 10,000 person-years.³⁴ Perforation leads to peritonitis from the release of contents into the abdominal cavity.³³ Patients with perforation will have intense abdominal pain, and because the ulcer may perforate to a nearby organ such as the liver or pancreas, amylase, lipase, and hepatic transaminases may be affected. If the perforation is treated quickly, the mortality rate is 6% to 14%, with poorer outcomes in patients with advanced age or major illness.³³

The duodenum can become narrowed from continued inflammation and scarring from ulcers, which may lead to gastric outlet obstruction.³³ Patients usually present with severe vomiting and hematemesis. Gastric outlet obstruction is rare, and physicians should consider an underlying malignancy in these patients.³⁵

Gastric cancer is the second leading cause of cancer-related mortality.³⁶ *H. pylori* has an epidemiologic role in the multifactorial process of gastric carcinogenesis.³⁷ It has virulence factors that directly influence cell transformation in those who have chronic *H. pylori* infection. It also causes chronic inflammation with an exaggerated immune response, which results in carcinogenesis. Although 50% of the world population is infected with *H. pylori*, less than 2% ever develop gastric cancer.³⁵

Data Sources: Essential Evidence Plus was searched using the key words duodenal ulcer, *Helicobacter*, *Helicobacter* infections, peptic ulcer, and stomach ulcer. This yielded InfoPOEMs, Cochrane reviews, and practice guidelines. The Trip database was also searched using the key words *Helicobacter pylori* and nonsteroidal anti-inflammatory drugs. Search date: November 27, 2013.

Table 5. Recommendations for *Helicobacter pylori* Infection in Children

Physicians should wait at least 2 weeks after the patient stops taking a proton pump inhibitor or 4 weeks after the patient stops taking an antibiotic to perform biopsy-based or noninvasive testing (e.g., urea breath test, stool test) for *H. pylori*.

Diagnostic testing for *H. pylori* is not recommended in children with functional abdominal pain.

In patients with peptic ulcer disease and *H. pylori* infection, the organism should be eradicated.

Tests based on the detection of antibodies (immunoglobulin G or A) against *H. pylori* are not reliable in clinical setting.

The urea breath test (carbon 13) is a reliable noninvasive test to determine whether *H. pylori* has been eradicated.

NOTE: Guideline from the European Society of Paediatric Gastroenterology, Hepatology, and Nutrition, and the North American Society of Pediatric Gastroenterology, Hepatology, and Nutrition. Grade of evidence: high (further research is unlikely to change the groups' confidence in the estimate of effect).

Information from reference 32.

The Authors

JULIA FASHNER, MD, is associate director of the Florida State University College of Medicine Family Medicine Residency at Lee Memorial Health System in Fort Myers.

ALFRED C. GITU, MD, is faculty at the Florida State University College of Medicine Family Medicine Residency at Lee Memorial Health System.

Address correspondence to Julia Fashner, MD, Lee Memorial Health System, 2780 Cleveland Ave., Ste. 709, Fort Myers, FL 33901 (e-mail: julia.fashner@leememorial.org). Reprints are not available from the authors.

REFERENCES

1. Talley NJ, Vakil N; Practice Parameters Committee of the American College of Gastroenterology. Guidelines for the management of dyspepsia. *Am J Gastroenterol*. 2005;100(10):2324-2337.

2. Malfertheiner P, Megraud F, O'Morain CA, et al.; European Helicobacter Study Group. Management of *Helicobacter pylori* infection—the Maas-tricht IV/ Florence Consensus Report. *Gut*. 2012;61(5):646-664.
3. Chey WD, Wong BC. American College of Gastroenterology guideline on the management of *Helicobacter pylori* infection. *Am J Gastroenterol*. 2007;102(8):1808-1825.
4. Ford AC, Delaney BC, Forman D, Moayyedi P. Eradication therapy for peptic ulcer disease in *Helicobacter pylori* positive patients. *Cochrane Database Syst Rev*. 2006;19(2):CD003840.
5. Papatheodoridis GV, Sougioultzis S, Archimandritis AJ. Effects of *Helicobacter pylori* and nonsteroidal anti-inflammatory drugs on peptic ulcer disease. *Clin Gastroenterol Hepatol*. 2006;4(2):130-142.
6. Salama NR, Hartung ML, Müller A. Life in the human stomach: persistence strategies of the bacterial pathogen *Helicobacter pylori*. *Nat Rev Microbiol*. 2013;11(6):385-399.
7. Federico A, Gravina AG, Miranda A, Loguercio C, Romano M. Eradication of *Helicobacter pylori* infection: which regimen first? *World J Gastroenterol*. 2014;20(3):665-672.
8. Moayyedi P, Talley NJ, Fennerty MB, Vakil N. Can the clinical history distinguish between organic and functional dyspepsia? *JAMA*. 2006;295(13):1566-1576.
9. Girdalidze AM, Elisabedashvili GV, Sharvadze LG, Dzhorbenadze TA. Comparative diagnostic value of *Helicobacter pylori* infection testing methods [in Russian]. *Georgian Med News*. 2013;(225):53-60.
10. Calvet X1, Sánchez-Delgado J, Montserrat A, et al. Accuracy of diagnostic tests for *Helicobacter pylori*: a reappraisal. *Clin Infect Dis*. 2009;48(10):1385-1391.
11. Shimoyama T. Stool antigen tests for the management of *Helicobacter pylori* infection. *World J Gastroenterol*. 2013;19(45):8188-8191.
12. Gisbert JP, Calvet X, O'Connor A, et al. Sequential therapy for *Helicobacter pylori* eradication. *J Clin Gastroenterol*. 2010;44(5):313-325.
13. Gisbert JP, Calvet X. Review article: non-bismuth quadruple (concomitant) therapy for eradication of *Helicobacter pylori*. *Aliment Pharmacol Ther*. 2011;34(6):604-617.
14. Wu DC, Hsu PI, Wu JY, et al. Sequential and concomitant therapy with four drugs is equally effective for eradication of *H pylori* infection. *Clin Gastroenterol Hepatol*. 2010;8(1):36-41.e1.
15. Molina-Infante J, Pazos-Pacheco C, Vinagre-Rodríguez G, et al. Nonbismuth quadruple (concomitant) therapy: empirical and tailored efficacy versus standard triple therapy for clarithromycin-susceptible *Helicobacter pylori* and versus sequential therapy for clarithromycin-resistant strains. *Helicobacter*. 2012;17(4):269-276.
16. Berning M, Krasz S, Miehlke S. Should quinolones come first in *Helicobacter pylori* therapy? *Therap Adv Gastroenterol*. 2011;4(2):103-114.
17. Gisbert JP, Khorrami S, Carballo F, Calvet X, Gené E, Dominguez-Muñoz JE. *H. pylori* eradication therapy vs. antisecretory non-eradication therapy (with or without long-term maintenance antisecretory therapy) for the prevention of recurrent bleeding from peptic ulcer. *Cochrane Database Syst Rev*. 2004;(2):CD004062.
18. Yuan Y, Ford AC, Khan KJ, et al. Optimum duration of regimens for *Helicobacter pylori* eradication. *Cochrane Database Syst Rev*. 2013;(12):CD008337.
19. Houben MH, van de Beek D, Hensen EF, de Craen AJ, Rauws EA, Tytgat GN. A systematic review of *Helicobacter pylori* eradication therapy—the impact of antimicrobial resistance on eradication rates. *Aliment Pharmacol Ther*. 1999;13(8):1047-1055.
20. Szajewska H, Horvath A, Piwowarczyk A. Meta-analysis: the effects of *Saccharomyces boulardii* supplementation on *Helicobacter pylori* eradication rates and side effects during treatment. [published correction appears in *Aliment Pharmacol Ther*. 2010;32(11-12):1408]. *Aliment Pharmacol Ther*. 2010;32(9):1069-1079.
21. Zou J, Dong J, Yu X. Meta-analysis: Lactobacillus containing quadruple therapy versus standard triple first-line therapy for *Helicobacter pylori* eradication. *Helicobacter*. 2009;14(5):97-107.
22. Lanza FL, Chan FK, Quigley EM; Practice Parameters Committee of the American College of Gastroenterology. Guidelines for prevention of NSAID-related ulcer complications. *Am J Gastroenterol*. 2009;104(3):728-738.
23. Rostom A, Dube C, Wells G, et al. Prevention of NSAID-induced gastroduodenal ulcers. *Cochrane Database Syst Rev*. 2002;(4):CD002296.
24. Rostom A, Moayyedi P, Hunt R; Canadian Association of Gastroenterology Consensus Group. Canadian consensus guidelines on long-term nonsteroidal anti-inflammatory drug therapy and the need for gastroprotection: benefits versus risks. *Aliment Pharmacol Ther*. 2009;29(5):481-496.
25. Vergara M, Catalán M, Gisbert JP, Calvet X. Meta-analysis: role of *Helicobacter pylori* eradication in the prevention of peptic ulcer in NSAID users. *Aliment Pharmacol Ther*. 2005;21(12):1411-1418.
26. Pilotto A, Franceschi M, Maggi S, et al. Optimal management of peptic ulcer disease in the elderly. *Drugs Aging*. 2010;27(7):545-558.
27. Hilton D, Iman N, Burke GJ, et al. Absence of abdominal pain in older persons with endoscopic ulcers. *Am J Gastroenterol*. 2001;96(2):380-384.
28. Fashner J, Gitu AC. Common gastrointestinal symptoms: risks of long-term proton pump inhibitor therapy. *FP Essent*. 2013;413:29-39.
29. Brown K, Lundborg P, Levinson J, Yang H. Incidence of peptic ulcer bleeding in the US pediatric population. *J Pediatr Gastroenterol Nutr*. 2012;54(6):733-736.
30. Spee LA, Madderom MB, Pijpers M, van Leeuwen Y, Berger MY. Association between *Helicobacter pylori* and gastrointestinal symptoms in children. *Pediatrics*. 2010;125(3):e651-e669.
31. Alarcón T, José Martínez-Gómez M, Urruzuno P. *Helicobacter pylori* in pediatrics. *Helicobacter*. 2013;18(suppl 1):52-57.
32. Koletzko S, Jones NL, Goodman KJ, et al. Evidence-based guidelines from ESPGHAN and NASPGHAN for *Helicobacter pylori* infection in children. *J Pediatr Gastroenterol Nutr*. 2011;53(2):230-243.
33. Ray WA, Chung CP, Stein CM, et al. Risk of peptic ulcer hospitalizations in users of NSAIDs with gastroprotective cotherapy versus coxibs. *Gastroenterology*. 2007;133(3):790-798.
34. Hernández-Díaz S, Rodríguez LA. Incidence of serious upper gastrointestinal bleeding/perforation in the general population: review of epidemiologic studies. *J Clin Epidemiol*. 2002;55(2):157-163.
35. Malfertheiner P, Chan FK, McColl KE. Peptic ulcer disease. *Lancet*. 2009;374(9699):1449-1461.
36. Conteduca V, Sansonno D, Lauletta G, Russi S, Ingravallo G, Dammacco F. *H. pylori* infection and gastric cancer. *Int J Oncol*. 2013;42(1):5-18.
37. Qadri Q, Rasool R, Gulzar GM, Naqash S, Shah ZA. *H. pylori* infection, inflammation and gastric cancer. *J Gastrointest Cancer*. 2014;45(2):126-132.